Cancer Treatment Today

Buprenorphin comes in a sublingual and transdermal formulation. In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. The transdermal form is well-established for treatment of chronic cancer pain and. It was

Antabuse, or disulfiram is approved for the treatment of alcohol abuse and alcohol dependence by the U.S. Food and Drug Administration. When alcohol is consumed it is metabolized by the body into acetaldehyde, and then into acetic acid, which is harmless. Antabuse interferes with this step, causing a buildup of acetaldehyde As a result, there is a build up of acetaldehyde five or 10 times greater than normally occurs when someone drinks alcohol.

There are many similarities between inpatient and outpatient alcohol rehab programs. Both types of treatment programs provide direction and guidance to the patients and their families to educate them about what alcoholism is and how to set and meet appropriate goals for treatment and recovery. Inpatient therapy involves a 24/7 stay in a residential treatment facility that is isolated from the outside world. The goal is to provide a setting that keeps

Intron A is a well established treatment for essential thrombocythemia (ET) and P. Vera, especially effective for control of pruritis. Interferon-(IFN) suppresses growth of multipotent hematopoietic progenitor cells. No leukemogenic risk has been reported. No randomized trials have been published. In the Italian guidelines for treatment of ET 15 studies have been summarized, including 292 patients. Complete normalization of platelet counts was achieved

Rehabilitation for alcohol and other drugs has proliferated and differentiated into many different clinical approaches during the last 40 years. After acute emdical care for detox, when necessary, as in this case, according to the duration, the amount of alcohol and other drugs taken and type of drugs abused, a person might either need a social detox or a medical detox.  Social detox may not be anything more than confined bed rest and someone to

Buprenorphin comes in a sublingual and transdermal formulation. In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. The transdermal form is well-established for treatment of chronic cancer pain and. It was